Search

Pearson Nurse's Drug Guide 2024 helps clinicians administer drugs safely in any health care setting. Drugs are listed alphabetically by generic name and indexed by both generic and trade name, enabling quick, easy lookup. The guide also gives you clinical information for hundreds of drugs, including adverse reactions, interactions, side effects and impact on lab results. Drug monographs deliver the data you need about each drug to adjust diagnoses and interventions. Combine this with detailed administration guidance and dosage information across the lifespan and you have an all-in-one guide to safe, effective drug administration in nearly any medical setting.

This introductory text explains both the basic science, production, quality, dosage forms, administration, economic and regulatory aspects and the clinical applications of biotechnology-derived pharmaceuticals. It serves as a complete one-stop source for undergraduate/graduate pharmacists and pharmaceutical science students. An additional important audience are pharmaceutical scientists in industry and academia, particularly those who have not received formal training in pharmaceutical biotechnology and are inexperienced in this field. The rapid growth and advances in the field made it necessary to revise this textbook in order to continue providing up-to-date information and introduce readers to cutting edge knowledge and technology of this field. This Sixth Edition completely updates the previous edition and includes additional coverage on new approaches such as oligonucleotides, siRNA, mRNA, gene therapy, cell therapies, monoclonal antibodies and vaccines. With more than 3-million-chapter downloads, the fifth edition of the textbook has achieved widespread distribution as a key educational resource for the field of pharmaceutical biotechnology.

This book offers an insightful exploration of drug repurposing, an innovative approach to drug discovery and development that has the potential to revolutionize the field of medicine. It begins with an introduction to drug repurposing and its history, providing a comprehensive overview of the subject. The readers will embark on a journey through the diverse landscape of drug repurposing strategies. From in silico methods of predicting drug-disease associations to experimental approaches to the integrations of artificial intelligence (AI) and machine learning (ML) in drug repurposing for validating repurposed candidates. The book also delves into the application of drug repurposing in various disease areas, including cancer, inflammatory disorders, and CNS disorders. It explores the potential hurdles involved in the regulatory aspects of the process. The book further covers drug products under clinical trials and provides an overview of the future perspectives of drug repurposing. With its detailed and informative content, this book is a must-read for researchers, clinicians, and healthcare professionals interested in the exciting field of drug repurposing.

Strategic decision-making focusing on economics is the fundamental requirement to generate efficiency and improve productivity in any manufacturing environment. In the 21st century, the science of drug development is an established field that requires a dedicated and synergistic partnership between various subject matter experts. Unfortunately, pharmaceutical research is complicated, time-consuming, attritive, and costly, with development costs ranging from $4 billion to $11 billion per commercialized drug. There are more than 750 biotech and big pharma companies in the US that are developing new drug products for a vast number of therapeutic indications. Due to the high attrition rate in clinical trials, a small percentage of these drugs get commercialized. Still, a very high amount of resources are being spent on drug development from a societal perspective. Despite being an economically intense activity, the current state of drug product development makes a limited effort to integrate economics into product design and development. For example, pharmaceutical scientists are excellent at a data-driven decision-making process that requires technical elements and a few strategic elements. However, there is minimal integration of financial valuation elements (commonly employed in other high-tech industries such as fine chemicals, automotive, aerospace, etc.) into pharmaceutical drug development. Unfortunately, this hurts the sustainability of the health system of which these products will be a part in the future. A desirable future state integrates fundamentals of economics in product design and development so that the decision-making is parameterized, the cost of goods can be lowered, wastage can be reduced, patient-centricity is built into the design, and manufacturing/distribution efficiencies can be gained. The financial benefits of such an approach could allow for these savings to be passed on to the stakeholders and improve the value proposition of pharmaceuticals, which is critical to maintaining the innovation potential. This book hopes to introduce the reader to this desired future state of pharmaceutical drug development.

After 18 years since the first biosimilar was approved, a lot has changed, from the regulatory guidelines to the stakeholder perceptions about the safety and efficacy of biosimilars. However, the development costs remain high, preventing faster entry into markets with more than 200 choices. Analyzing the regulatory filings of all approved biosimilars in the US and EU, a deep analysis of the scientific principles, and continuous challenges to the regulatory authorities have made it possible to plan the development on a fast track. This book teaches how to cut the current time and cost by more than 70%, based on the author's hands-on experience.Features: Describes the emergence of biosimilars since the first publication of the recombinant engineering patent, as well as a listing of all approved recombinant products, their patent expiry and their adoption across the globe. Provides a better understanding of the safety and efficacy of approved biosimilars. Global approval requires accommodating guidelines and detailed planning to avoid redundancy as well as high costs. The basic expectations of the agencies are presented here. Presents a detailed analysis of all EU and FDA-approved products with a comparative analysis. Renowned author and entrepreneur in the field of drug discovery and production.

Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders focuses on 3D printing, bioprinting, microfluidics, organ-on-a-chip systems, and molecular modeling. The book, written by a team of leading experts in the field, is an essential resource for anyone interested in the future of CRD treatment. Chapters discuss the emerging therapeutic approaches for CRDs, including biologicals and phytoceuticals. Core chapters of the book then cover the application of 3D printing, bioprinting, microfluidics, organ-on-a-chip systems, and molecular modeling to different CRDs. The book concludes with a discussion of the current clinical trials and future prospects for the management of CRDs.This is a valuable resource for researchers, clinicians, and other healthcare professionals who are interested in the latest technological advances in the field of CRDs. It will also be of interest to students and scientists working in the fields of pharmaceutical sciences, microfluidics, bioinformatics, drug design, drug delivery, and 3D printing. - Provides the most recent and updated perspectives and challenges in the management of chronic respiratory disorders - Covers exciting new technologies such as 3D printing, bioprinting, microfluidics, organ-on-a-chip systems, and molecular modelling - Includes the most recent information on the development of advanced drug delivery systems for the treatment of chronic respiratory disorders

A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Third Edition is a valuable reference providing a complete understanding of all aspects of nonclinical toxicology in pharmaceutical research. This updated edition has been expanded and re-developed covering a wide-range of toxicological issues in small molecules and biologics. Topics include ADME in drug discovery, pharmacokinetics, toxicokinetics, formulations, and genetic toxicology testing. The book has been thoroughly updated throughout to reflect the latest scientific advances and includes new information on antiviral drugs, anti-diabetic drugs, immunotherapy, and a discussion on post-pandemic drug development challenges and opportunities. This is an essential and practical resource for all toxicologists involved in nonclinical testing in industry, academic, and regulatory settings. - Provides updated, unique content not covered in one comprehensive resource, including chapters on stem cells, antiviral drugs, anti-diabetic drugs, and immunotherapy - Includes the latest international guidelines for nonclinical toxicology in both small and large molecules - Incorporates practical examples in order to illustrate day-to-day activities and expectations associated with working in nonclinical toxicology

Grunnleggende kunnskaper i klinisk farmakologi og legemiddelhåndtering er nødvendige for sikker og effektiv behandling av pasienter. Denne boka gir deg kunnskapsgrunnlaget for å utføre legemiddelrelaterte arbeidsoppgaver, som å gi legemidler, informere pasienter om bruk av legemidler og effekten av dem, observere og overvåke pasienten og handle raskt dersom det oppstår komplikasjoner, og rapportere om og dokumentere virkning og bivirkninger. For best mulig læringsutbytte anbefaler vi at du først leser del 1, som gir en generell, overordnet innføring i farmakologien, og del 2, som viser hvordan legemidler påvirker ulike sykdomsprosesser. Del 3 handler om legemiddelbehandling ved sykdommer i de enkelte organene og organsystemene. Del 4 tar for seg bruk av legemidler hos spesielle pasientgrupper og ved spesielle tilstander. I denne delen omtales også legemidler til gravide og barn, legemidler mot akutte forgiftninger og plantebaserte legemidler. Boken inngår i kunnskapspakken 37 ºC, som består av fem lærebøker i de naturvitenskapelige fagene for sykepleierutdanningen. Selv om de fem bøkene er utviklet som en helhet, er konseptet fleksibelt, og hver enkelt bok kan brukes uavhengig av de andre bøkene i serien.

Der Arzneiverordnungs-Report ist seit 1985 eine gemeinsame Publikation von Autoren aus Pharmakologie, Klinik, Praxis, Gesundheitsökonomie und Krankenversicherung. Basis sind die Verordnungsdaten von Arzneimitteln für ambulante Patienten der gesetzlichen Krankenversicherung (GKV).

Polymer-Drug Conjugates: Linker Chemistry, Protocols and Applications discusses important concepts, fundamentals and prospective applications of'Linker Chemistry'in a clear-and-concise manner. The book provides vital information on chemical entities binding with the drug-polymer complex for targeted drug delivery systems. It highlights roles and significance, different classes and synthetic protocols as well as mechanisms of chemical bond formation in drug-polymer conjugation in drug delivery, also offering insights into the mechanism of polymer interaction with linker and drug molecules by biodegradable chemical bonding. The protocol of binding with drug molecules is clearly explained and justified with case studies, helping researchers and advanced students in the pharmaceutical sciences understand fundamentals involved and related aspects in molecule designing for effective therapeutic benefits. - Covers mechanism, protocol and therapeutic significance of Polymer-Drug Conjugates - Outlines updated methods and techniques to enumerate conjugation with related case studies - Includes comprehensive compilation of marketed and clinical trial drugs conjugated with polymers or linkers

Pharmaceutical Biotechnology in Drug Development summarizes key concepts and the latest developments of biotechnology applied to the development of biopharmaceuticals. Chapters present a comprehensive collection of introductory biotechnology technologies and their modern concepts and cover pharmacokinetic and pharmacodynamic behavior of biopharmaceuticals and modification techniques of amino acids and nucleic acid. Other sections focus on topics such as gene therapy, immunological preparations and nanoparticles which are the major contributions of pharmaceutical biotechnology. Final chapters discuss emerging techniques in the field of pharmaceutical biotechnology to meet current patient and health care demand. This book is an essential reference useful for pharmaceutical scientists, clinicians and academic researchers who want easy access to up-to-date practices of pharmaceutical biotechnology. Corporate researchers will also benefit from this book's succinct and objective content structure. - Includes key concepts at the foundation of the technology and relevant for protein therapeutics - Explains how advances in other areas such as genomics, proteomics and high-throughput screening have paved the way for exploring new avenues of drug discovery - Covers the importance of biotechnology in the development of new biopharmaceuticals, along with their pharmacodynamics and pharmacokinetics

Formulation of Monoclonal Antibody Therapies: From Lab to Market covers a wide range of topics about therapeutic monoclonal antibodies (mAbs) with a focus on formulation aspects. Therapeutic monoclonal antibodies are used for treatment of chronic diseases. It brings together a comprehensive knowledge in one accessible volume. Starting with foundational information on monoclonal antibodies, the book then discusses the importance of biopharmaceutical products, monoclonal antibodies, and biosimilars in treatment of chronic diseases, pharmaceutical aspects of mAbs, and how it can be administered. It also covers the industrial point of view and the clinical application of mAbs including in oncology, general medicine, rheumatology, hematology, dermatology, gastrointestinal tract, metabolic diseases, and dentistry. Formulation of Monoclonal Antibody Therapies: From Lab to Market is essential reading for researchers in biotechnology and biopharmaceutical fields, academics and pharmaceutical industrial scientists, and university students in pharmaceutical and biopharmaceutical sciences. - Covers details of recent advances in using mAbs - Examines how to overcome the challenges for formulations of therapeutic mAbs - Includes clinical application of mAbs

Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics. - Provides accurate reviews from leading experts on the topic of pulmonary pharmacology - Each chapter of the volume provides consolidated graphical materials for ease of reading for the audience - Provides the latest insights and future perspectives on the drug discovery and development for respiratory diseases

Der Arzneiverordnungs-Report ist seit 1985 eine gemeinsame Publikation von Autoren aus Pharmakologie, Klinik, Praxis, Gesundheitsökonomie und Krankenversicherung. Basis sind die Verordnungsdaten von Arzneimitteln für ambulante Patienten der gesetzlichen Krankenversicherung (GKV).

Lantibiotics as Alternative Therapeutics explores alternative therapeutics, lantibiotics and other novel drugs. This book provides concrete information to readers regarding lantibiotics and various types of antimicrobial peptides with their mode of actions in treating various multidrug resistant organisms. It explains various techniques that are involved in analyzing antimicrobial peptides and their mode of actions. The development of antibiotic resistance has now reached a point of crisis where innovative methods and application of novel compounds and methods are required to prevent the spread of drug resistant infections. Novel compounds exhibit different modes of action to the currently used mechanism of therapeutics in order to combat against the resistant organisms. Lantibiotics hold considerable potential as a consequence of their unusual structure, unique mechanisms of action and their potency against multi-drug resistant bacteria. This book will be useful for pharmaceutical industry scientists and researchers in microbial and biomedical research as well as graduate and advanced students in microbiology, medical biotechnology, health, and pharmaceutical sciences. - Includes the biology, molecular interaction with target molecule, putative genes and analytical techniques to isolate and identify compounds - Incorporates relevant case studies to increase understanding - Focuses on recent trends on novel antimicrobial agents and antibiotic resistance research - Discusses new arena of diseases, apart from acute and chronic infections

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Comprehensive Pharmacology, Seven Volume Set is organized into twelve sections that explore therapeutic areas, with a total of 320 comprehensive articles and 6,800 pages of important findings. Sections contain highly detailed coverage of information that has been overseen by an editorial board made up of well-respected, field leading experts. The content in this book offers readers an in-depth and easily accessible reference work on every aspect of pharmacological research surrounding the pharmacology of all therapeutic applications of drugs, their mechanism of action and their therapeutic values. These elements are essential as drugs are almost never tested and developed in the actual therapeutic system, but rather in test systems from which parameters must be determined to predict activity in systems of varying ambient physiology. As different technologies rapidly evolve, there is an ever-increasing level of knowledge about the pharmacology of known drugs, along with increasing capability to utilize pharmacological systems to predict new drug activity, all of which must be communicated to professionals in varying fields. - Contains chapters that follow a consistent and templated approach, resulting in well-structured content that enhances user experience and appeal - Offers a comprehensive review on a wealth of information on pharmacology and how it utilizes concepts and techniques from a broad array of sciences, ranging from chemistry to physiology to medicine - Includes a wider use of color and multimedia content, with interactive features, links, computational modeling and animations to illustrate the effects of toxic substances in various contexts

Biologics and Biosimilars: Drug Discovery and Clinical Applications is a systematic integration and evaluation of all aspects of biologics and biosimilars, encompassing research and development, clinical use, global regulation, and more. Biosimilars are biological therapeutic agents designed to imitate a reference biologic with high similarities in structure, efficacy, and safety, but also with potential clinical effective and cost-efficient options for the manufacturers, payers, clinicians, and patients. Most of the top-selling prescription drugs in the current market are biologics, which have revolutionized the treatment strategies and modalities for life-threatening and/or rare diseases.This book outlines the key processes and challenges in drug development, regulations, and clinical applications of biologics, biosimilars, and even interchangeable biosimilars. Global experts in the field discuss essential categories and prototype drugs of biologics and biosimilars in clinical practice such as allergenics, blood and blood components, cell treatment, gene therapy, recombinant therapeutic proteins or peptides, tissues, and vaccines.Additional features: Integrates the latest bench and bedside evidence of drug development and regulations of biologics and biosimilars Contains key study questions for each chapter to guide the readers, as well as drug charts for all therapeutic applications of biologics and biosimilars Presents detailed schematic illustrations to explain the drug development, clinical trials, regulations, and clinical applications of biologics and biosimilars This book is an invaluable tool for health care professional students, providers, and pharmaceutical and health care industries, as well as the public, providing readers with educational updates about the drug development and clinical affairs of biological medications and their similar drugs.

Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals provides scientists responsible for the translation of novel biopharmaceuticals into clinical trials with a better understanding of how to navigate the obstacles that keep innovative medical research discoveries from becoming new therapies or even making it to clinical trials. The book includes sections on protein-based therapeutics, modified proteins, oligonucleotide-based therapies, monoclonal antibodies, antibody–drug conjugates, gene and cell-based therapies, gene-modified cell-based therapies, combination products, and therapeutic vaccines. Best practices are defined for efficient discovery research to facilitate a science-based, efficient, and predictive preclinical development program to ensure clinical efficacy and safety.Key Features: Defines best practices for leveraging of discovery research to facilitate a development program Includes general principles, animal models, biomarkers, preclinical toxicology testing paradigms, and practical applications Discusses rare diseases Discusses'What-Why-When-How'highlighting different considerations based upon product attributes. Includes special considerations for rare diseases About the EditorsJoy A. Cavagnaro is an internationally recognized expert in preclinical development and regulatory strategy with an emphasis on genetic medicines.. Her 40-year career spans academia, government (FDA), and the CRO and biotech industries. She was awarded the 2019 Arnold J Lehman Award from the Society of Toxicology for introducing the concept of science-based, case-by-case approach to preclinical safety evaluation, which became the foundation of ICH S6. She currently serves on scientific advisory boards for advocacy groups and companies and consults and lectures in the area of preclinical development of novel therapies.Mary Ellen Cosenza is a regulatory toxicology consultant with over 30 years of senior leadership experience in the biopharmaceutical industry in the U.S., Europe, and emerging markets. She has held leadership position in both the American College of Toxicology (ACT) and the International Union of Toxicology (IUTOX) and is also an adjunct assistant professor at the University of Southern California where she teaches graduate-level courses in toxicology and regulation of biologics.

This fully updated third edition of the encyclopedia covers all aspects of pharmacology, from the chemistry of drugs and the biochemistry of drug targets to the clinical application of drugs, with emphasis on molecular mechanisms. It also includes techniques for describing the effects of drugs and characterizing drug targets. With over 2,000 entries and 350 detailed essays by leading experts, this book is also an up-to-date and important reference for scientists in fields outside pharmacology, students, health care workers, teachers, physicians, and laypersons. Available both in print and as a fully searchable and hyperlinked electronic online edition.

The Handbook of Systemic Drug Treatment in Dermatology helps prescribers and patients make rational decisions about drug treatment while considering known risks and potential unwanted effects. Written for dermatologists, family practitioners, pharmacists and specialist nurses, this completely revised and updated third edition of a bestseller provides an accessible and concise aid to prescribing and monitoring systemic dermatologic therapy. For each drug or drug class, the book lists its classification, mode of action, formulations, dosages, suggested regimens, contraindications, important drug interactions, adverse effects, patient information, and more. This third edition includes new classes of drugs as well as information on updated guidelines for prescribing and monitoring established drugs.FROM REVIEWS OF PREVIOUS EDITIONS'This updated edition includes new arrivals… Quite simply, it is indispensable! I have it with me in every clinic and often refer to it in discussions with pharmacists (who have been known to borrow my copy and forget to return it).'Dermatology in Practice'... an outstanding resource that helps to alleviate worrying by providing precise guidelines and advice in managing our most infirm patients who require these medications.'SkinMed

Allergy is the most frequent chronic disease in the 21st century having severe negative effects on health and the economy. The challenge we therefore face in medicine and science incorporates all areas of society – from politics to food industry, from schools to city planning, and many more. This volume informs the reader about continuously ongoing developments in allergy research and their implications for society. The chapter sections cover the immunological mechanisms in allergy on a molecular level, describe the triggers and cures for allergy in detail, entail clinical translation of lab findings on allergens, evaluate diagnostics for allergy markers, and provide solutions for future medical intervention or preventive strategies. Laboratory research, bioinformatics, climate modelling, patient treatment, intervention studies, epigenetics and multiple other disciplines are able to shed new light on this revolutionary field of healthcare.

Monoclonal antibodies (mAbs) are naturally occurring complex biomolecules. New engineering methods have turned mAbs into a leading therapeutic modality for addressing immunotherapeutic challenges and led to the rise of mAbs as the dominant class of protein therapeutics. mAbs have already demonstrated a great potential in developing safe and reliable treatments for complex diseases and creating more affordable healthcare alternatives. Developing mAbs into well-characterized antibody therapeutics that meet regulatory expectations, however, is extremely challenging. Obstacles to overcome include the determination and development of physiochemical characteristics such as aggregation, fragmentation, charge variants, identity, carbohydrate structure, and higher-order structure (HOS). This book dives deep into mAbs structure and the array of physiochemical testing and characterization methods that need to be developed and validated to establish a mAb as a therapeutic molecule. The main focus of this book is on physiochemical aspects, including the importance of establishing quality attributes such as glycosylation, primary sequence, purity, and HOS and elucidating the structure of new antibody formats by mass spectrometry. Each of the aforementioned quality attributes has been discussed in detail; this will help scientists in researching and developing biopharmaceuticals and biosimilars to find practical solutions to physicochemical testing and characterization. - Describes the spectrum of analytical tests and characterization methods necessary for developing and releasing mAb batches - Details antibody heterogeneity in terms of size, charge, and carbohydrate content - Gives special focus to the structural analysis of mAbs, including mass spectrometry analysis - Presents the basic structure of mAbs with clarity and rigor - Addresses regulatory guidelines - including ICH Q6B - in relation to quality attributes - Lays out characterization and development case studies including biosimilars and new antibody formats

Recent research in science establishes a direct relation between human gut and skin. Several species of live microbes inhabit the human skin and intestines which far outnumbers the mammalian cells in the human body. Research interest of Nextgen scientists is focused on beneficially harnessing this microbial population to address skin disorders like acne, rosacea, eczema, premature aging, and skin cancer which are established to be a result of skin-microbiome dysbiosis. This volume highlights evidence-based endeavours of the scientific community in this sector. Currently there is no concrete literature which gives a detailed vision on the relationship between gut microbiota and skin related disorders. This volume is an attempt to put together available data in the area and demonstrate usefulness of probiotics as a new therapeutic option for management of these skin diseases which currently show poor prognosis, high cost of treatment and compromised quality of life of the patient.

Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term'children'is used ambiguously to confer physiological characteristics to a chronological age limit, which in reality does not exist. This book outlines why the United States (US) and European Union's (EU) regulatory authorities, pediatric academia, and the pharmaceutical industry demand, support and perform pediatric drug studies, along with the key flaws of this demand that blurs the different administrative and physiological meanings of the term'child.'In addition, the book covers why most pediatric regulatory studies lack medical sense and many even harm young patients and the conflicts of interest behind pediatric drug studies. It includes relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs as well as key differences between newborns, infants, older children and adolescents. - Explains relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs, including key differences between newborns, infants, older children and adolescents - Discusses historical roots of separate drug approval in officially labeled'children'and conflicts of interest in performing and publishing'pediatric'research - Helps to decipher justifications for pediatric studies to help people navigate the relevance of the information

This volume provides readers with the most updated scientific information on the efficacy and safety of medicines for children and adolescents. The book enriches the understanding of pediatric pharmacotherapy for health professionals, regulatory agencies, pharmaceutical companies and learned societies. It contains important information on the pharmacodynamics and pharmacokinetics of drugs. It summarizes the latest investigations on the effects of pharmacological treatments in relation to and dependent on age, gender, fat mass and disease status. Therefore and importantly, this volume reviews the latest data on how pharmacotherapy has to be adjusted and personalized in regards to stages of development and during the pediatric lifespan from neonate through adolescence. In addition, the topic of rare diseases and special challenges for pharmacotherapy will be included and will provide readers with the necessary knowledge to handle complex diseases and treatment strategies especially in relation to pharmacotherapy of rare and orphan diseases.

Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents provides sound data on the utility of biological and plant-based drugs and describes challenges faced in all aspects offering indispensable strategies to use in the development of bioactive medicines. Bioactive based medications are commonly used throughout the world and have been recognized by physicians and patients for their therapeutic efficacy. Bioactive formulations, including their subordinates and analogs, address 50% of all medicines in clinical practice. Novel bioactive medicine transporters can cure many disorders by both spatial and transitory approaches and have various justifications in medicinal potential. This book presents information on the utility of natural, plant, animal and bioengineered bioactive materials. It is a fundamental source of information and data for pharmacognosists, pharmaceutical analysts, drug transport scientists and pharmacologists working in bioactive medications. - Advances information on various bioactive based medications, their sources, clinical consequences and transport strategies - Illustrates diverse transport systems for bioactives and derivatives, novel techniques for formulations, targeting strategies and fundamental qualities of developed bioactive carriers, and their safety concerns and standardization - Discusses distinctive transport systems, stability, upgraded dissolvability, and enhanced bioavailability of bioactives

Inhalation aerosols continue to be the basis for successful lung therapy for several diseases, with therapeutic strategies and the range of technology significantly evolving in recent years.In response, this third edition takes a new approach to reflect the close integration of technology with its application. After briefly presenting the general considerations that apply to aerosol inhalation, the central section of the book uses the focus on disease and therapeutic agents to illustrate the application of specific technologies.The final integrated strategies section draws the major points from the applications for disease targets and drug products.

Medicine has entered a golden age in which therapeutic agents are becoming widely available due to advances in basic science and technology. As such, many drugs have been developed that target inflammatory processes and/or the immune system. This book is intended for health professionals examining the modulation of inflammation by immunotherapeutic drugs. The immune system fills the primordial role of host defense and resistance to infections with pathogenic microorganisms. Several hematopoietic-derived cells constituting the innate and adaptive immune systems cooperate to provide barriers for microbial colonization and/or promote pathogen destruction within the host. Conversely, many immune cells are also involved in the pathogenesis and propagation of chronic inflammatory diseases. The beginning of this book details various components of the immune system including the cell types, lymphoid tissues, soluble cytokines and surface molecules that are essentialfor host defense. Breakdowns in immune tolerance, or dysregulated immune responses to antigens derived from self tissues or innocuous sources, can lead to the development of autoimmunity or chronic inflammatory diseases. Pathophysiologic roles for the immune system are detailed in corresponding chapters on autoimmunity, epithelial surfaces (lungs, skin, intestine), and transplantation, with special emphasis placed on immunotherapeutic drug targets. The last section of the book focuses on treatments that stimulate our immune system to specifically target and fight infectious diseases and cancer. In each chapter, the medications used to treat various diseases/conditions in terms of their mechanism of action and other pharmacologic properties are detailed. Chapters begin with a table showing drug names and classifications. The importance of basic science and clinical trials cannot be understated in the context of drug development. As such, the discovery of certain medicationsthat had a lasting impact in medicine and pharmacy are highlighted in chapter subsections named “Bench to Bedside.” Several clinical applications of immunotherapeutic drugs are described within end-of -chapter case studies including practice questions. The Pharmacology of Immunotherapeutic Drugs is a reference for immunologists and clinicians (medical doctors, pharmacists, nurses) examining the modulation of inflammatory processes by a variety of medications targeting the cells and mediators of our immune system.​

Genomic and Precision Medicine: Infectious and Inflammatory Disease, Third Edition, provides current clinical solutions on the application of genome discovery on a broad spectrum of disease categories in IMD - including asthma, obesity and multiple sclerosis. Each chapter is organized to cover the application of genomics and personalized medicine tools and technologies, along with information on a) Risk Assessment and Susceptibility, b) Diagnosis and Prognosis, c) Pharmacogenomics and Precision Therapeutics, and d) Emerging and Future Opportunities in the field. - Offers comprehensive coverage of infectious and inflammatory disease genomics - Provides succinct commentary and key learning points to assist providers with the implementation of genomic and personalized medicine - Presents an up-to-date overview on major opportunities for genomic and personalized medicine - Includes case studies that highlight the practical use of genomics in the management of patients